ArticleBMC neurology2025
Integrating single-cell RNA-Seq and machine learning to dissect a novel Palmitoylation-related prognostic signature of glioblastoma.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) represents a profoundly aggressive and heterogeneous brain neoplasm linked to a bleak prognosis. Palmitoylation plays a key role in the development and progression of GBM, but its molecular mechanism and prognostic significance in GBM are still not fully understood. This study aims to explore the prognostic biomarkers of GBM based on palmitoylation-related genes.
methodsEight scoring methods, including AUCell, UCell, singscore, ssGSEA, JASMINE, VAM, scSE, and viper, were used to score each sample. In addition, the palmitoylation score calculated by the AUCell algorithm is selected as the representative. In order to screen the genes related to GBM survival and build a risk prognosis model, 101 algorithms constructed by 10 kinds of machine learning are arranged and combined for variable screening and model building, and then immune infiltration and immunotherapy evaluation, drug screening, and molecular docking are carried out.
resultsWe observed that macrophages in GBM cell types have the highest palmitoylation score. The secondary dimensionality reduction clustering of macrophages showed that the palmitoylation of PLCG2 + macrophages was significantly higher than that of other subtypes, and three core prognostic genes (ZDHHC2, ZDHHC4, ZDHHC20) were screened out by machine learning. A higher risk score is significantly related to worse clinical status and most immune labels. Among them, ZDHHC2 was significantly up-regulated in GBM in several verification groups. Molecular docking found that quercetin was the best targeted drug for ZDHHC2.
conclusionThis study revealed for the first time the heterogeneity of palmitoylation at the GBM single-cell level. The identification of ZDHHC2, ZDHHC4, and ZDHHC20 as key regulators of palmitoylation in GBM emphasized their potential as biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.